Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 131

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 131
---
 supplies of products. Additionally, macro-economic conditions
may adversely affect these third parties, causing them to suffer liquidity or operational problems. If a key third-party vendor becomes
insolvent or is forced to lay off workers assisting with our projects, our results and development timing could suffer.

In addition, any products that we may develop may
compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers
that operate under cGMP regulations that may be capable of manufacturing for us. Our anticipated future dependence upon others for the
manufacture of product candidates or products may adversely affect our future profit margins and our ability to commercialize any products
that receive marketing approval on a timely and competitive basis.

Data provided by collaborators and other parties
upon which we rely has not been independently verified and could turn out to be inaccurate, misleading, or incomplete.

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then we would intend to rely on third-party vendors, scientists, and collaborators to provide us
with significant data and other information related to our projects, clinical trials, and business. In addition, we would likely not independently
verify or audit all such data (including possibly material portions thereof), and therefore, any such potential future data may be inaccurate,
misleading, or incomplete.

Risks Related to Intellectual
Property 

If we are able to raise sufficient capital and
potentially license or acquire new technologies, we may be unable to obtain and maintain intellectual property protection for these technologies
or products we plan to license or develop or if the scope of the intellectual property protection obtained is not sufficiently broad,
our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully
commercialize our technology and products may be impaired. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then our success depends in large part on our ability to obtain and maintain patent protection in
the United States, the European Union, and other countries with respect to proprietary technology and products we plan to develop. We
will seek to protect our proprietary position by filing patent applications in the United States and internationally that are related
to novel technologies and product candidates.

 18 

The patent prosecution process is expensive and time-consuming,
and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.
We may choose not to seek patent protection for certain innovations and may choose not